1. Exposure‐Response to SC Ustekinumab In Moderate‐Severe Crohn's Disease: Results From the IM‐UNITI Maintenance Study: 660. (October 2017) Authors: Adedokun, Omoniyi J.; Xu, Zhenhua; Gasink, Christopher; Jacobstein, Douglas; Szapary, Philippe; Johanns, Jewel; Gao, Long Long; Davis, Hugh M.; Hanauer, Stephen; Feagan, Brian G.; Ghosh, Subrata; Sandborn, William J. Journal: American journal of gastroenterology Issue: Volume 112(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. (3rd June 2019) Authors: Hanauer, Stephen B; Sandborn, William J; Feagan, Brian G; Gasink, Christopher; Jacobstein, Douglas; Zou, Bin; Johanns, Jewel; Adedokun, Omoniyi J; Sands, Bruce E; Rutgeerts, Paul; de Villiers, Willem J S; Colombel, Jean-Frédéric; Ghosh, Subrata Journal: Journal of Crohn's and colitis Issue: Volume 14:Number 1(2020) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P034 EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE AT MAINTENENCE WEEK 56: IM-UNITI STUDY. (7th February 2019) Authors: Sandborn, William J; Sands, Bruce E; Colombel, Jean-Frederic; Gasink, Christopher; Patel, Rishit; Jacobstein, Douglas; Gao, Long-long; Ghosh, Subrata; Targan, Stephan; De Villiers, Willem; Hanauer, Stephen B; Rutgeerts, Paul; Feagan, Brian G Journal: Inflammatory bowel diseases Issue: Volume 25(2019)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pregnancy Outcomes in Women Exposed to Ustekinumab in the Crohn's Disease Clinical Development Program: 611. (October 2017) Authors: Scherl, Ellen J.; Jacobstein, Douglas; Murphy, Conor; Ott, Elyssa; Gasink, Christopher; Baumgart, Daniel C.; Abraham, Bincy; Targan, Stephan R. Journal: American journal of gastroenterology Issue: Volume 112(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Response and Remission After 16 Weeks of Ustekinumab: An All Patients Analysis From the UNITI Crohn's Studies: 718. (October 2017) Authors: Colombel, Jean‐Frederic; Sloan, Sheldon; Gasink, Christopher; Gao, Long Long; Jacobstein, Douglas; Lee, Scott D.; Targan, Stephan R. Journal: American journal of gastroenterology Issue: Volume 112(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety of Ustekinumab With and Without Concomitant Corticosteroids or Immunosuppressants in Patients With Moderately to Severely Active Crohn's Disease: 608. (October 2017) Authors: Sands, Bruce E.; Gasink, Christopher; Jacobstein, Douglas; Ott, Elyssa; Lang, Yinghua; Ramachandran, Paraneedharan; Ghosh, Subrata Journal: American journal of gastroenterology Issue: Volume 112(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. (3rd May 2018) Authors: Sands, Bruce E; Han, Chenglong; Gasink, Christopher; Jacobstein, Douglas; Szapary, Philippe; Gao, Long-Long; Lang, Yinghua; Targan, Stephan; Sandborn, William J; Feagan, Brian G Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 8(2018:Aug.) Page Start: 883 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Tolerability of Ustekinumab in Induction and Maintenance for the Treatment of Crohn's Disease: 658. (October 2017) Authors: Loftus, Edward V.; Sattin, Bernie; Jacobstein, Douglas; Gasink, Christopher; Sloan, Sheldon; Feagan, Brian G.; Colombel, Jean‐Frederic Journal: American journal of gastroenterology Issue: Volume 112(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study. (26th May 2021) Authors: Rosh, Joel R; Turner, Dan; Griffiths, Anne; Cohen, Stanley A; Jacobstein, Douglas; Adedokun, Omoniyi J; Padgett, Lakshmi; Terry, Natalie A; O'Brien, Christopher; Hyams, Jeffrey S Journal: Journal of Crohn's and colitis Issue: Volume 15:Number 11(2021) Page Start: 1931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Ustekinumab IV Induction Results in Crohn's Disease Symptom Improvement Within the First Week in Anti‐TNF Refractory Patients: 730. (October 2017) Authors: Sandborn, William J.; Yeager, Benjamin; Gasink, Christopher; Hoops, Timothy; Gao, Long Long; Wang, Yanli; Jacobstein, Douglas; Lee, Scott D.; Hanauer, Stephen Journal: American journal of gastroenterology Issue: Volume 112(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗